JPRN-UMIN000020416已完成未知
Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study - Regorafenib versus TAS-102: a multicenter, retrospective observational study (REGOTAS)
Japanese Society for Cancer of the Colon and Rectum0 个研究点目标入组 600 人开始时间: 2016年1月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
Whether unadjusted analysis or adjusted analysis was established, regorafenib and trifluridine/tipiracil showed a similar efficacy in the overall survival of? patients with metastatic colorectal cancer refractory to standard treatments in the real-world setting.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Prior therapy with regorafenib or TAS-102 2) Active infections 3) Symptomatic brain metastasis 4) Active double cancers 5) Serious complications 6) Uncontrolled thromboembolism 7) Comorbidity with systemic steroid therapy
研究者
相似试验
招募中
2 期
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRCMetastatic Colorectal CancerNCT05970705Fudan University101
已完成
不适用
A retrospective analysis of regorafenib and TAS-102 for advanced or recurrent colorectal cancerJPRN-UMIN000024116Sapporo City General Hospital18
终止
2 期
Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT04450836UNICANCER234
招募中
不适用
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted TherapyTranscatheter Arterial ChEmoembolizationHepatocellular CarcinomaRegorafenibNCT05811481WenBo Guo192
尚未招募
3 期
Benefits of a combination of chemotherapy tablets and injectable targeted therapy versus using a targeted therapy tablet alone in colorectal cancer patientsCTRI/2023/04/051850Tata Memorial Hospital